MR-proADM: A Stable Adrenomedullin Fragment Identified as a Sepsis Biomarker

A mid-regional pro-adrenomedullin fragment (MR-proADM) was identified in sepsis patient plasma as a stable, measurable surrogate for adrenomedullin — laying the groundwork for what became a major clinical sepsis biomarker.

Struck, Joachim et al.·Peptides·2004·Moderate Evidenceclinical-trial
RPEP-00981Clinical TrialModerate Evidence2004RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

A mid-regional pro-adrenomedullin (MR-proADM) fragment was identified and quantified in sepsis patient plasma, providing a stable, measurable surrogate for the unstable mature adrenomedullin — establishing the basis for clinical MR-proADM sepsis testing.

Key Numbers

How They Did This

clinical-trial study on neuropeptides, cardiovascular.

Why This Research Matters

Relevant for neuropeptides, cardiovascular, clinical-trials.

The Bigger Picture

Advances peptide therapeutics/biomarker research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding A mid-regional pro-adrenomedullin (MR-proADM) fragment was identified and quantified in sepsis patient plasma, providing a stable, measurable surrogat
Evidence Grade:
moderate evidence.
Study Age:
Published in 2004.
Original Title:
Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients.
Published In:
Peptides, 25(8), 1369-72 (2004)
Database ID:
RPEP-00981

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What was studied?

MR-proADM: A Stable Adrenomedullin Fragment Identified as a Sepsis Biomarker

What was found?

A mid-regional pro-adrenomedullin fragment (MR-proADM) was identified in sepsis patient plasma as a stable, measurable surrogate for adrenomedullin — laying the groundwork for what became a major clinical sepsis biomarker.

Read More on RethinkPeptides

Cite This Study

RPEP-00981·https://rethinkpeptides.com/research/RPEP-00981

APA

Struck, Joachim; Tao, Chen; Morgenthaler, Nils G; Bergmann, Andreas. (2004). Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients.. Peptides, 25(8), 1369-72.

MLA

Struck, Joachim, et al. "Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients.." Peptides, 2004.

RethinkPeptides

RethinkPeptides Research Database. "Identification of an Adrenomedullin precursor fragment in pl..." RPEP-00981. Retrieved from https://rethinkpeptides.com/research/struck-2004-identification-of-an-adrenomedullin

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.